Sanofi submits new diabetes drug application to U.S. regulator
{{#rendered}} {{/rendered}}The Sanofi logo is seen at the company's headquarters in Lyon, France, October 26, 2015. French drugs firm Sanofi will present its Q3 results on October 29. REUTERS/Robert Pratta (Copyright Reuters 2015)
French drugmaker Sanofi said on Wednesday it had submitted an application to the U.S. Food and Drug Administration (FDA) for a single daily insulin injection to treat adults with type 2 diabetes.
Sanofi said it had requested a six-month review of its new drug application by the FDA, rather than the standard 10 months.
"A large unmet medical need still exists for people with type 2 diabetes, as more than half are not at their blood sugar goal despite using oral medications or insulin," Sanofi's diabetes head, Pierre Chancel, said in a statement.
{{#rendered}} {{/rendered}}The latest application involves a combination of insulin glargine with its lixisenatide drug, Sanofi said.